Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

10.7%

11 terminated/withdrawn out of 103 trials

Success Rate

71.8%

-14.7% vs industry average

Late-Stage Pipeline

10%

10 trials in Phase 3/4

Results Transparency

0%

0 of 28 completed trials have results

Key Signals

21 recruiting9 terminated

Enrollment Performance

Analytics

Phase 2
36(43.4%)
N/A
36(43.4%)
Phase 4
5(6.0%)
Phase 3
5(6.0%)
Phase 1
1(1.2%)
83Total
Phase 2(36)
N/A(36)
Phase 4(5)
Phase 3(5)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (103)

Showing 20 of 103 trials
NCT07738094Not ApplicableRecruiting

Cold and NSAID Trial for Prevention of Post-ERCP Pancreatitis

Role: lead

NCT04498260Phase 4Completed

Intralesional Steroid Injection Versus Oral Prednisolone in Prevention of Esophageal Stricture

Role: lead

NCT06070376Not ApplicableRecruiting

Comparative Study Between (FC-SEMS) and (PC-SEMS) in the Palliation of Dysphagia Due to Malignant Neoplasm of Esophagus.

Role: lead

NCT06077981Not ApplicableRecruiting

Comparison of 0.4% Hyaluronic Acid Solution Versus Hydroxyethylamide Solution in Submucosal Endoscopic Resections

Role: lead

NCT07632638Not ApplicableRecruiting

Safety and Performance Evaluation of the RonovoTM Robotic Surgical Platform in Oncological Procedures

Role: lead

NCT07066046Not ApplicableRecruiting

Artificial Intelligence-assisted Colonoscopy in the Detection and Characterization of Colorectal Lesions

Role: lead

NCT07644455Not ApplicableNot Yet Recruiting

Percutaneous Biopsy After Neoadjuvant Chemotherapy.

Role: lead

NCT07463092Not ApplicableRecruiting

Creatine Supplementation and Resistance Training to Improve Sarcopenia Parameters in Patients With Prostate Cancer After Androgen Deprivation Therapy

Role: collaborator

NCT07600515Not Yet Recruiting

Evaluation of Persistent Infection by Oncogenic Human Papillomavirus (HPV) in Patients Treated for Cervical Carcinoma and Its Relation to Prognostic Factors

Role: lead

NCT07316686Phase 1Not Yet Recruiting

Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma

Role: lead

NCT06638931Phase 2Recruiting

Agnostic Therapy in Rare Solid Tumors

Role: lead

NCT05622136Phase 2Active Not Recruiting

Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma

Role: lead

NCT06435286Phase 2Recruiting

Effectiveness and Performance of an Optical Biopsy Technology for Esophageal Cancer in Brazil and the United States

Role: collaborator

NCT07432360Recruiting

Detecting Clinically Significant Prostate Cancer With Advanced MRI Protocols and Extensive Histopathology

Role: collaborator

NCT07376317Phase 2Active Not Recruiting

Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS)

Role: lead

NCT06640283Phase 2Recruiting

Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes

Role: lead

NCT05354778Not ApplicableRecruiting

HYDROcortisone Versus Placebo for Severe HospItal-acquired Pneumonia in Intensive Care Patients: the HYDRO-SHIP Study

Role: collaborator

NCT06978673Not ApplicableNot Yet Recruiting

Neurolytic Block Techniques In Abdominal Visceral Cancer Pain

Role: lead

NCT06982274Phase 2Recruiting

Oral Arsenic With ATRA for Newly Diagnosed Patients With Acute Promyelocytic Leukemia

Role: lead

NCT06988865Completed

Benign Migratory Glossitis Associated With Antiangiogenic Drugs

Role: lead